REMISSION INDUCTION IN ACUTE NONLYMPHOCYTIC LEUKEMIA - COMPARISON OF A 7-DAY AND 10-DAY INFUSION OF CYTOSINE-ARABINOSIDE IN COMBINATION WITH ADRIAMYCIN

被引：39

作者：

PREISLER, H

BJORNSSON, S

HENDERSON, ES

HRYNIUK, W

HIGBY, D

FREEMAN, A

NAEHER, C

机构：

[1] Department of Medicine A, Roswell Park Memorial Institute, Buffalo, New York

[2] Department of Pediatrics, Roswell Park Memorial Institute, Buffalo, New York

[3] Computer Center, Roswell Park Memorial Institute, Buffalo, New York

[4] Department of Medicine, University of Manitoba, Winnipeg

来源：

MEDICAL AND PEDIATRIC ONCOLOGY | 1979年 / 7卷 / 03期

关键词：

Adriamycin – cytosine arabinoside; AML treatment;

D O I：

10.1002/mpo.2950070313

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Forty‐six previously untreated patients with acute nonlymphocytic leukemia were treated with a remission induction regimen consisting of three daily doses of Adriamycin (30 mg/m2/day) and a ten‐day continuous infusion of cytosine ara binoside (ara C) (100 mg/m2/day). The overall remission rate was 72%, with 88% of the patients < 50 and 62% of patients > 50 years old achieving complete remission status. Thirty‐one of the 33 complete remissions occurred after a single course of chemotherapy. Retrospective comparison of this regimen with its predecessor (identical, except that a seven‐day infusion of ara C was administered) demonstrated that the increase in duration of ara C administration resulted in greater antileukemic effectiveness without an increase in hematologic toxicity to the patient. Copyright © 1979 Wiley‐Liss, Inc., A Wiley Company

引用

页码：269 / 275

页数：7

共 9 条

[1]

Preisler HD, Rustum Y, Henderson ES, Et al., Treatment of acute nonlymphocytic leukemia: Use of anthracycline cytosine arabinoside induction therapy and a comparison of two maintenance regimens, Blood, 53, pp. 455-464, (1979)

[2]

Preisler HD, Failure of remission induction during the treatment of acute leukemia, Med Pediatr Oncol, 4, pp. 275-276, (1978)

[3]

Preisler HD, Bjornsson S, Henderson ES, Adriamycin‐cytosine arabinoside therapy for adult myelocytic leukemia, Cancer Treat Rep, 61, pp. 89-92, (1977)

[4]

Ohnuma T, Rosner F, Levy RN, Et al., Treatment of adult leukemia with L‐asparaginase, Cancer Chemother Rep, 55, pp. 269-275, (1971)

[5]

Frei E, Bickers JN, Hewlett JS, Et al., Dose schedule and antitumor studies of arabinosyl cytosine (NSC 63878), Cancer Res, 28, pp. 1325-1332, (1969)

[6]

Hinterberger W, Mittermayer K, Kinort H, Et al., Action of humoral factors derived from acute and chronic myeloid leukemic cells on in vitro myelopoiesis, Oncology, 34, pp. 193-197, (1977)

[7]

Broxmeyer HE, Jacobsen N, Kinland J, Et al., In vitro suppression of normal granulocytic stem cells by inhibitory activity derived from human leukemia cells, J Natl Cancer Inst, 60, pp. 497-511, (1978)

[8]

Gale RP, Cline MJ, High remission induction rate in acute myeloid leukemia, Lancet, 1, pp. 497-499, (1977)

[9]

Rees JKH, Sandler RN, Challener J, Et al., Treatment of acute myeloid leukaemia with a triple cytotoxic regimen: DAT, Br J Cancer, 36, pp. 770-776, (1977)

← 1 →